Molekulare Pathogenese von Schilddrüsentumoren

Schlüsselwörter

Schilddrüsentumore - Molekulare Pathogenese

Key words

thyroid tumors - molecular pathogenesis

Literatur

• 1 Ciampi R, Knauf J A, Kerler R. et al . Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer.  J Clin Invest. 2005;  115 94-101
• 2 Fagin J A. Minireview: branded from the start-distinct oncogenic initiating events may determine tumor fate in the thyroid.  Mol Endocrinol. 2002;  16 903-911
• 3 Fagin J A. Challenging dogma in thyroid cancer molecular genetics - role of RET/PTC and BRAF in tumor initiation.  J Clin Endocrinol Metab. 2004;  89 4264-4266
• 4 Krohn K, Fuhrer D, Bayer Y. et al . Molecular pathogenesis of euthyroid and toxic multinodular goiter.  Endocr Rev. 2005;  26 504-524
• 5 Kroll T G, Sarraf P, Pecciarini L. et al . PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma (corrected).  Science. 2000;  289 1357-1360
• 6 Nikiforova M N, Lynch R A, Biddinger P W. et al . RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma.  J Clin Endocrinol Metab. 2003;  88 2318-2326
• 7 Parma J, Duprez L, Van Sande J. et al . Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas.  Nature. 1993;  365 649-651